Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

endocrine · Mechanism Report

Can low morning cortisol, reduced androgen bioavailability, HSD11B1 tissue cortisol variation, and inflammatory signaling contribute to fatigue and weight variability in postmenopausal women?

In postmenopausal women, this endocrine-inflammatory pattern is associated with fatigue and weight variability.

PlausibleJuly 20, 202621 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Low morning cortisol, reduced androgen bioavailability, HSD11B1-related tissue cortisol variation, and inflammatory signaling can interact to produce fatigue and weight variability through overlapping effects on circadian HPA rhythm, local glucocorticoid signaling, and postmenopausal steroid-hormone output.

laying out figure…
3 of 7 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim describes a combined effect of blunted morning cortisol, reduced active androgen availability, and inflammatory signaling on tiredness and fluctuating weight. The mechanism framing centers on HSD11B1-driven local cortisol regeneration, which can both shift fat deposition and reduce androgen bioavailability, while low-grade inflammation adds to fatigue pathways.

Verified conclusion

In postmenopausal women, the intersection of endocrine shifts and chronic inflammatory pathways creates a distinct metabolic profile that simultaneously drives physical exhaustion and weight fluctuations.

Clinical and metabolic evidence

  • HPA Axis Dysregulation: Blunted morning cortisol and flattened diurnal HPA rhythms directly correlate with daytime exhaustion, non-restorative sleep, and fatigue in menopausal cohorts, while disrupting systemic energy regulation.
  • Androgen Bioavailability: In postmenopause, 11-oxygenated androgens like 11-ketotestosterone become the dominant active circulating androgens. A decline in their bioavailability impairs muscle mass maintenance and alters lipid accumulation, contributing directly to physical fatigue and metabolic-syndrome-like weight variations.
  • Inflammatory Signaling: Chronic low-grade inflammation ("inflammaging") and altered adipokine expression directly trigger central fatigue pathways and impair iron utility (manifesting as low ferritin), driving persistent tiredness.

Mechanistic pathways

  • HSD11B1 Activity: Postmenopausal estrogen decline upregulates 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) in visceral adipose tissue and the liver. This accelerates the local regeneration of active cortisol from inactive cortisone, causing localized glucocorticoid excess that drives visceral fat deposition.
  • Enzymatic Crosstalk: Upregulated HSD11B1 acts as a metabolic switch that clears and inactivates active 11-oxygenated androgens. This dual mechanism simultaneously promotes local cortisol-driven fat accumulation and deprives tissues of energy-sustaining androgens.

Bottom line

  • In postmenopausal women, upregulated tissue HSD11B1 acts as a critical metabolic hub that drives visceral weight gain and depletes active androgens. This local steroid imbalance, paired with systemic HPA axis flattening and chronic low-grade inflammation, forms a synergistic network that explains co-occurring fatigue and weight fluctuations.

References

  1. Cortisol and Menopause — positivepause.co.uk ↗
  2. L'impact du cortisol à la ménopause : ses effets sur le corps — alexiacornu.com ↗
  3. Menopause, Cortisol, & Adrenal Fatigue | MMP Ep.19 — youtube.com ↗
  4. Inhibition of the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 drives concurrent 11-oxygenated androgen excess — faseb.onlinelibrary.wiley.com ↗
  5. Inhibition of the glucocorticoid-activating enzyme 11β ... — biorxiv.org ↗
  6. Hepatic metabolism of 11-oxygenated androgens in humans — academic.oup.com ↗
  7. 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and ... — academic.oup.com ↗
  8. The Accumulation of Visceral Fat in Postmenopausal Women — imrpress.com ↗
  9. Tissue-Specific Increases in 11β-Hydroxysteroid ... - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  10. Tissue-Specific Increases in 11β-Hydroxysteroid ... — journals.plos.org ↗
  11. Association of estrogen with glucocorticoid levels in visceral fat in postmenopausal women - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  12. 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) ... — nature.com ↗
  13. Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  14. [PDF] Estrogen and Glucocorticoid Metabolism - Diva-Portal.org — diva-portal.org ↗
  15. The Role of microRNA in the Regulation of Cortisol Metabolism in the Adipose Tissue in the Course of Obesity — mdpi.com ↗
  16. Cortisol as a factor contributing to the development of non-alcoholic fatty liver disease in severely obese patients: a single-center prospective study — amsad.termedia.pl ↗
  17. Inflammation and iron homeostasis - what do blood tests mean? — pmc.ncbi.nlm.nih.gov ↗
  18. Fatigue in Perimenopause and Menopause — jumpstartmd.com ↗
  19. Fatigue After Menopause: Causes, What Helps, and Lab Tests — vitalsvault.com ↗
  20. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial — cmaj.ca ↗
  21. Effect of iron therapy on fatigue symptoms in non-anaemic iron deficient women of reproductive age- A Randomized Controlled Trial. — jpma.org.pk ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesCan obstructive sleep apnea lower testosterone in men?→Plausible5 sourcesDoes a non-elevated LH with low testosterone suggest secondary hypogonadism?→